- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00880789
Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus (ACT-CAT)
Adoptive Transfer of Cord Blood T Cells To Prevent and Treat CMV and Adenovirus Infections After Transplantation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
We plan to grow T cells from the cord blood in the laboratory in a special way, to see if they can help prevent or treat infections in transplant patients with these viruses. This therapy with specially trained T cells (called CTLs) has had activity against these viruses when the cells are made from donor blood and given to patients receiving bone marrow or blood stem cell transplants. We want to find out if we can use CTLs that we will make from cord blood to prevent or treat viral infections when the patient's immunity is weak after receiving the cord blood transplant. These cells are called "CMV/AdV specific CTLs" because they can attack those two viruses.
The doctor will already have found a cord blood unit that is suitable for the patient's transplant. If the patient agrees to this study we will take 5-10 ml (1-2 teaspoons) from this cord blood unit before the transplant. We will only take as much cord blood as is available in a specially frozen small fraction of the cord blood unit.
We will use this cord blood to grow T cells in the lab. From this blood we will first grow special type of cells called dendritic cells and we will put a specially produced human virus (adenovirus) that carries the CMVpp65 gene into these dendritic cells. The dendritic cells will be irradiated so they cannot grow and then used to stimulate the T cells. This stimulation will train the T cells to kill cells with CMV and adenovirus on their surface.
We will then grow large numbers of these AdV/CMV-specific CTLs by more stimulation with EBV infected B cells (which we will make from the cord blood by infecting them with EBV in the laboratory). We will also put the special virus into these B cells so that they too have AdV/CMV. Again, these B cells will be treated with radiation so they cannot grow. Once we have made enough T cells we will test them to make sure they kill cells infected with Adenovirus and CMV. To make sure that these cells won't attack the patient's own healthy tissues, we test these cells against some of the blood cells that we will grow in the laboratory. These will be used to check to see if the AdV/CMV CTL can attack them. Alternatively, we may take blood from a first degree relative or take a small piece of skin from the patient to grow skin cells, which can also to be used to check if AdV/CMV CTL can attack them. The skin biopsy can be done at the same time as another procedure such as a bone marrow biopsy.
The cord donor's AdV/CMV CTL cells will be thawed and injected into the IV line over a period of up to 10 minutes.Patients may be premedicated with Benadryl and Tylenol. If the patient agrees and if he/she is well enough, one dose of CTL will be given on or after day 30 following transplant. If the patient does not have AdV/CMV infection we will not give antiviral medications to them during this study but we will monitor the patient closely to check for AdV/CMV infection. If the patient does have AdV/CMV infection before CTL infusion they may also be treated with antiviral medications during this study. We will monitor the patients closely for AdV/CMV infection by collecting blood and possibly urine and stool and testing them for AdV/CMV.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Texas Children's Hospital
-
Houston, Texas, United States, 77030
- Houston Methodist Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
INCLUSION CRITERIA:
Inclusion criteria at the time of Procurement:
- Patient with malignant or nonmalignant diseases who are candidates for transplant.
- Patients must have a single CB unit matched with the patient at 4, 5, or 6/6 HLA class I (serological) and II (molecular) antigens. The unit must be cryopreserved in two fractions, with a minimum of 2.5x10^7 total nucleated cells per kg pre-thaw in the fraction which will be used for the primary transplant. The remaining fraction will be used to generate the CTLs to give at day 30 or beyond as described below.
Inclusion criteria at the time of CTL infusion:
- Recipients of a single cord blood unit fractionated into 2 fractions (i.e. from a HLA matched or mismatched unrelated donor) transplant at risk for or with CMV/Adenoviral disease or reactivation.
- Lansky/Karnofsky scores 60 or greater
- Absolute neutrophil count (ANC) greater than 500/ul.
- No evidence of GVHD > Grade II at time of enrollment.
- Life expectancy > 30 days
- Absence of severe renal disease (Creatinine > x 3 normal for age)
- Absence of severe hepatic disease. Direct bilirubin must be less than 3 mg/dl and AST less than 5x upper limit of normal
- Patient must be at least 30 days post transplant to be eligible to receive CTL
- Written informed consent and/or signed assent line from patient, parent or guardian.
- Patient not on Fi02 of >60%
EXCLUSION CRITERIA:
Exclusion criteria at the time of Procurement:
- Pregnant or Lactating
- Patients with active central nervous system disease
- Patients with Karnofsky performance status <70%
- Patients with grade 3 or 4 or primary myelofibrosis
- Patients with suitable related donors
Exclusion criteria at the time of CTL infusion:
- Pregnant or lactating
- Unable to wean steroids to 0.5 mg/kg/day or less prednisone.
- Patients with other uncontrolled infections (except CMV and/or adenovirus and/or EBVemia in absence of PTLD). For bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment. For fungal infections patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment. Progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.
- Patients with less than 50% donor chimerism in either peripheral blood or bone marrow or patients with relapse of original disease.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Dose Level One: 5x10^6/m2
CTL Dose Given from Day +30 post SCT (stem cell transplant).
For the trial, two patients are allocated in each cohort and are followed for 30 days post IV injection of transduced T-cells for evaluation of DLTs.
A maximum 18 patients will be accrued into each group.
The final MTD will be the dose with probability closest to the target toxicity rate at these termination points.
The trial continues until a minimum of 12 patients have been treated.
The trial will stop when the maximum 18 patients have been treated, or when six patients have been treated at the current MTD.
We therefore expect to enroll between 12-18 patients into this trial.
|
CTL Dose Given from Day +30 post SCT (stem cell transplant).
For the trial, two patients are allocated in each cohort and are followed for 30 days post IV injection of transduced T-cells for evaluation of DLTs.
A maximum 18 patients will be accrued into each group.
The final MTD will be the dose with probability closest to the target toxicity rate at these termination points.
The trial continues until a minimum of 12 patients have been treated.
The trial will stop when the maximum 18 patients have been treated, or when six patients have been treated at the current MTD.
We therefore expect to enroll between 12-18 patients into this trial.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine safety, toxicity and MTD of one intravenous injection of donor-derived cytotoxic T lymphocytes (CTLs) specific for CMV and Adenovirus given to patients with or at risk for CMV and adenovirus disease after cord blood transplant
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the feasibility of generating a sufficient number of umbilical cord blood-derived cytotoxic T lymphocytes (CTLs) specific for CMV and Adenovirus
Time Frame: 1 year
|
1 year
|
To evaluate the impact of these CTLs on Adenovirus-specific T-lymphocyte immune reconstitution.
Time Frame: 1 year
|
1 year
|
To evaluate the recovery of virus-specific immunity after CTL infusion and its correlation with viral clearance and/or protection from viral infection/disease.
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Caridad A. Martinez, MD, Baylor College of Medicine - Texas Children's Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 23668-ACT CAT
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cytomegalovirus Infection
-
The George Washington University Biostatistics...Eunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedCongenital Cytomegalovirus Infection | Maternal Cytomegalovirus InfectionUnited States
-
Merck Sharp & Dohme LLCCompletedCytomegalovirus Infection | Cytomegalovirus DiseaseJapan
-
Jun ZhangNational Natural Science Foundation of China; Merck Sharp & Dohme LLCCompletedCongenital Cytomegalovirus Infection | Cytomegalovirus Infection ReactivationChina
-
Merck Sharp & Dohme LLCCompletedCytomegalovirus InfectionUnited States, France, Germany, Italy, Japan, United Kingdom
-
Foundation IRCCS San Matteo HospitalFondazione Regionale per la Ricerca Biomedica (FRRB) - Regione LombardiaUnknownCongenital Cytomegalovirus Infection | Maternal Cytomegalovirus InfectionItaly
-
Assistance Publique - Hôpitaux de ParisCompletedFoetuses Infection | Cytomegalovirus (CMV)InfectionFrance
-
National Institute of Allergy and Infectious Diseases...Terminated
-
Institut PasteurCompletedCongenital Cytomegalovirus InfectionFrance
-
Assistance Publique - Hôpitaux de ParisCompletedCongenital Cytomegalovirus InfectionFrance
-
Jun ZhangCompletedCongenital Cytomegalovirus InfectionChina
Clinical Trials on CMV/AdV specific T cells
-
Catherine BollardM.D. Anderson Cancer CenterRecruitingViral InfectionUnited States
-
Prof. Tobias FeuchtingerEuropean Commission; Simbec-Orion Group Ltd, Merthyr Tydfil, UK; Miltenyi Biotec... and other collaboratorsRecruitingCMV Infection | EBV Infection | Stem Cell Transplant Complications | AdV InfectionBelgium, Spain, France, Germany, Italy, Netherlands
-
AlloVirBaylor College of Medicine; The Methodist Hospital Research Institute; Center...WithdrawnAdenovirus InfectionUnited States
-
Central Hospital, Nancy, FranceCompleted
-
Cell Medica LtdTechnology Strategy Board, United KingdomCompletedADV Infection Post Allo-HSCTUnited Kingdom
-
H. Kim LyerlyNational Cancer Institute (NCI); National Institutes of Health (NIH)TerminatedAllogeneic Stem Cell TransplantationUnited States
-
M.D. Anderson Cancer CenterMiltenyi Biotec B.V. & Co. KGCompletedLymphoma | LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingDiffuse Large B-Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Mantle Cell Lymphoma | B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Transformed Non-Hodgkin LymphomaUnited States
-
University of Wisconsin, MadisonUniversity of Wisconsin Carbone Cancer Center (UWCCC)RecruitingCytomegalovirus Infections | Opportunistic Infections | CMV Infection | CMV ViremiaUnited States
-
University of Wisconsin, MadisonTerminatedCytomegalovirus Infections | Solid Organ TransplantUnited States